[
  {
    "section": "section:1",
    "title": "Abstract"
  },
  {
    "section": "section:2",
    "title": "Background"
  },
  {
    "section": "section:2",
    "title": "Methods"
  },
  {
    "section": "section:2",
    "title": "Result"
  },
  {
    "section": "section:2",
    "title": "Conclusions"
  },
  {
    "section": "section:2",
    "title": "Trial registration"
  },
  {
    "section": "section:1",
    "title": "Background"
  },
  {
    "section": "section:1",
    "title": "Methods"
  },
  {
    "section": "section:2",
    "title": "Pyrimidine metabolism as a starting pathway to find more genes in the gemcitabine pharmacologic pathway"
  },
  {
    "section": "section:2",
    "title": "Adding more potentially related proteins to the pathway using comprehensive PPI data"
  },
  {
    "section": "section:2",
    "title": "Finding common SNPs in the Singaporean population"
  },
  {
    "section": "section:2",
    "title": "Five criteria to filter candidate SNPs"
  },
  {
    "section": "section:2",
    "title": "Study population"
  },
  {
    "section": "section:2",
    "title": "Blood collection and genomic DNA extraction"
  },
  {
    "section": "section:2",
    "title": "PCR (polymerase chain reaction) and pyrosequencing"
  },
  {
    "section": "section:2",
    "title": "Statistical analysis to find correlation between the candidate SNPs and patient outcome"
  },
  {
    "section": "section:1",
    "title": "Results"
  },
  {
    "section": "section:2",
    "title": "5046 nsSNPs were found to be linked to the 178 genes in the gemcitabine pharmacologic pathway"
  },
  {
    "section": "section:2",
    "title": "15 out of 77 common nsSNPs have significant results in three out of five criteria"
  },
  {
    "section": "section:2",
    "title": "Genotyping of the six final candidate SNPs"
  },
  {
    "section": "section:2",
    "title": "ABCG2 Q141K and SLC29A3 S158F are associated with increased survival in NSCLC"
  },
  {
    "section": "section:2",
    "title": "ABCG2 Q141K and POLR2A N764K are correlated with gemcitabine cytotoxicity"
  },
  {
    "section": "section:1",
    "title": "Discussion"
  },
  {
    "section": "section:1",
    "title": "Conclusions"
  },
  {
    "section": "section:1",
    "title": "Additional file"
  },
  {
    "section": "section:1",
    "title": "Abbreviations"
  },
  {
    "section": "section:1",
    "title": "Authors’ contributions"
  },
  {
    "section": "section:1",
    "title": "Funding"
  },
  {
    "section": "section:1",
    "title": "Availability of data and materials"
  },
  {
    "section": "section:1",
    "title": "Authors’ contributions"
  },
  {
    "section": "section:1",
    "title": "Ethics approval and consent to participate"
  },
  {
    "section": "section:1",
    "title": "Competing interests"
  },
  {
    "section": "section:1",
    "title": "Publisher’s Note"
  },
  {
    "section": "section:1",
    "title": "Author details"
  },
  {
    "section": "section:1",
    "title": "References"
  }
]